Tiziana Life Sciences Ltd (NASDAQ:TLSA) will present at the Webull LIVE! with Corporate Connect: Virtual Biotech Investment Webinar on December 6th at 3:00 PM ET. Matthew Davis, COO and CMO, will discuss recent clinical updates and the Phase 2 trial of intranasal foralumab, a human anti-CD3 monoclonal antibody, targeting non-active secondary progressive multiple sclerosis and neuroinflammatory diseases. The focus extends to neurodegenerative conditions like Alzheimer’s. Interested participants can register at https://us02web.zoom.us/webinar/register/WN_9-kFpy_DQ8OlBAoDQg8D7w.
The Markets by Proactive
Go to Proactive Australia
Proactive’s Australian coverage continues on .com